UroSens Announces Name Change to Arquer Diagnostics Ltd
News Jul 21, 2015
UroSens Ltd has announced it has changed its name to Arquer Diagnostics Ltd (Arquer). As part of the name change, the Company has undergone a total brand refresh, which will see the implementation of a new visual identity and online presence to support Arquer’s future plans, evolution and growth, with immediate effect.
The rebranding reflects the progression of the Company’s strategic focus, beyond prostate and bladder cancer into diagnostics for multiple cancers of the urinogenitary tract, including colorectal and cervical cancers.
The Company has also announced that it has expanded its laboratory space at the North East Business and Innovation Centre, Sunderland, UK, from 300 sq ft to 1555 sq ft. The growth of the Company follows a £2 million ($3 million USD) investment in Arquer, in December last year, which has enabled expansion of the commercial and technical teams. The funding has also enabled Arquer to begin to commercialise its diagnostic test, the Mcm5-ELISA, which is expected to significantly reduce the number of patients undergoing invasive and costly biopsies, because it offers highly accurate diagnostic results from small amounts of body fluid.
Mcm5 (minichromosome maintenance complex component 5) is a protein which only appears when cells divide, and is a marker for the presence of dividing cancer cells. Arquer’s test is based on intellectual property licensed exclusively from Cancer Research Technology (CRT), the development and commercialisation arm of Cancer Research UK.
Dr Ian Campbell, CEO at Arquer, commented: “This is a very exciting time for the Company. As we expand our focus into new areas we are taking the opportunity to update and strengthen how we represent ourselves, in line with our strategy. The rebranding represents our ambitions to bring our novel assay to the market, providing patients with a simple non-invasive test for cancers of the urinogenitary tract.”
Arquer will officially celebrate its new brand with clients and contacts at Medica 2015, 16-19th November, Düsseldorf.
Scientists have identified sodium glucose transporter 2 (SGLT2) as a mechanism that lung cancer cells can utilize to obtain glucose, which is key to their survival and promotes tumor growth. The finding provides evidence that SGLT2 may be a novel biomarker that scientists can use to help diagnose precancerous lung lesions and early-stage lung cancers.READ MORE